Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/34956/000135448811002180/oxbt_10k.htm
EXHIBIT 99.1
Contact:
Ellen Corliss
Vice President
Corporate Communications
& Investor Relations
(919) 855-2112
Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2011
MORRISVILLE, NC, July 14, 2011 — Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) ended April 30, 2011.
R&D Highlights
|
●
|
Completed the first cohort of our STOP-TBI Phase IIb clinical trial and initiated efforts to expand trials to India. Received DSMB approval to proceed to second cohort of the STOP-TBI Phase IIb clinical trial.
|
|
●
|
Entered into a Cooperative Research and Development Agreement with the U.S. Naval Medical Research Center to conduct additional preclinical trials to assess the safety and efficacy of Oxycyte for the prevention and treatment of decompression sickness and related injuries.
|
|
●
|
U.S. Navy studies demonstrated decreased mortality in models that were given an intravenous dose of Oxycyte PFC emulsion after the onset of decompression sickness. This data was published in the June 2010 issue of Aviation Space and Environmental Medicine.
|
|
●
|
Signed research contract funded by the Department of Defense with Hackensack University Medical Center to study the wound healing properties of Wundecyte™ gel. Studies are underway.
|
|
●
|
Signed a Letter of Intent with Sarasota Medical Products to pursue joint research and development in chronic ischemic wound care.
|
Corporate Highlights
|
●
|
Raised $4.9 million in a private placement of Unregistered Convertible Notes and Warrants in June 2011.
|
|
●
|
Received $2.07 million two-year grant from the U.S. Army to study the use of Oxycyte® perfluorocarbon (PFC) emulsion for traumatic brain injury.
|
|
●
|
Raised nearly $5 million from a registered direct offering in May 2010.
|
DERMACYTE® Highlights
|
●
|
Launched two oxygenating skin care products, DERMACYTE Concentrate and DERMACYTE Oxygenating Eye Complex in the U.S. via internet sales and direct sales to dermatologists and medi-spas.
|
|
●
|
Expanded international sales of DERMACYTE by entering into agreements with two distributors that will sell DERMACYTE® skin care products in the Swiss, Mexican, European and Russian markets.
|
|
●
|
Secured listings on leading on-line beauty retail websites for DERMACYTE skin care products: www.Dermstore.com and www.Beautyriche.com
|
The following information was filed by Tenax Therapeutics, Inc. (TENX) on Friday, July 15, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Tenax Therapeutics, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Tenax Therapeutics, Inc..
TENX Annual Reports
Material Contracts, Statements, Certifications & more
Tenax Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Ticker: TENX
CIK: 34956
Form Type: 10-K Annual Report
Accession Number: 0001354488-11-002180
Submitted to the SEC: Thu Jul 14 2011 6:38:39 PM EST
Accepted by the SEC: Fri Jul 15 2011
Period: Saturday, April 30, 2011
Industry: Commercial Physical And Biological Research
External Resources:
Insider Transactions
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/tenx/0001354488-11-002180.htm
